Potential serum biomarkers of treatment response to ustekinumab in patients with psoriasis: a pilot study
| Autor: | Errol P. Prens, Arne IJpma, Ewout M. Baerveldt, Armanda J. Onderdijk, S.P. Menting |
|---|---|
| Přispěvatelé: | Dermatology, Pathology |
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class Pilot Projects Dermatology Monoclonal antibody Etanercept Psoriasis Area and Severity Index Psoriasis Ustekinumab Adalimumab medicine Humans biology business.industry Th1 Cells medicine.disease Infliximab Up-Regulation Treatment Outcome Immunology biology.protein Cytokines Th17 Cells Dermatologic Agents Antibody business Biomarkers Signal Transduction medicine.drug |
| Zdroj: | British Journal of Dermatology, 173(6), 1536-1539. Wiley-Blackwell Publishing Ltd British journal of dermatology, 173(6), 1536-1539. Wiley-Blackwell |
| ISSN: | 0007-0963 |
| DOI: | 10.1111/bjd.13997 |
| Popis: | Currently available biologics for psoriasis target the function of TNF-α, IL-17A or IL-12/23 and include etanercept (anti-TNF receptor fusion protein), adalimumab and infliximab (anti-TNFα antibodies), anti-IL-17(receptor) molecules and ustekinumab. Ustekinumab is a fully human immunoglobulin monoclonal antibody targeting the p40 subunit shared by IL-12 and IL-23. This prevents binding to the IL-12Rβ1 receptor unit on immune cells and subsequent signaling. The Psoriasis Area and Severity Index (PASI) is used for evaluation of the efficacy of therapies in psoriasis. This article is protected by copyright. All rights reserved |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text